NEW YORK, Sept. 3, 2019 /PRNewswire/ -- The Mesothelioma Victims Center says, "Many Navy Veterans with mesothelioma do not realize their net financial compensation settlement could exceed a million dollars. We also want to emphasize these compensation settlements do not involve suing the US Navy as we'd like to discuss at 800-714-0303. We have endorsed the law firm of

PULLMAN, Wash., Sept. 3, 2019 /PRNewswire/ -- PhD programs used to be difficult to find in an online format but that isn't the case today, especially with degrees in the healthcare field or related fields. Your work schedule can make it feel impossible to get back into a classroom, but if you're open to a virtual one, there are many options. Recently, OnlineCollegeP

VANCOUVER, Sept. 3, 2019 /PRNewswire/ - CRH Medical Corporation (the "Company") (TSX: CRH) (NYSE MKT: CRHM), announces that it has completed an accretive transaction whereby the Company has acquired the remaining 49% interest in Central Colorado Anesthesia Associates, LLC, ("CCAA") a gastroenterology anesthesia practice located in

RANCHO CORDOVA, Calif., Sept. 3, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced Jeff Cauble, Vice President of Finance and Principal Accounting Officer, will present at the H.C. Wainwright 21st Annual Global Investment Confer

ELMSFORD, N.Y., Sept. 3, 2019 /PRNewswire/ -- NanoVibronix,

Company's 26th Florida Location Invites Community to FREE Weekly Educational Seminars PORT CHARLOTTE, Fla., Sept. 3, 2019 /PRNewswire/ -- Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading vertically integrated cannabis operator in the United States, announced today the open

TORRANCE, Calif., Sept. 3, 2019 /PRNewswire/ -- Emmaus Life Sciences, Inc. (Nasdaq: EMMA), a leader in sickle cell disease treatment, announced today the allowance of patent application number 12860587.0, directed to the treatment of diverticulosis, by the European Patent Office. The allowance of this application follows the issuance of corresponding patents in

NEW YORK, Sept. 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the company will present at three conferences in

BERLIN, Sept. 3, 2019 /PRNewswire/ -- Bayer today announced Marianne De Backer PhD as the new Head of Business Development & Licensing of its Pharmaceuticals Division. She will report to Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of the company's Pharmaceuticals Division and join the Pharmaceuticals

SOUTH SAN FRANCISCO, Calif., Sept. 3, 2019 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc. ("Satsuma" or "the Company"), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today announced that it will be presenting two posters at the 19th Congress of the International Headache